by Desiree Cobb-Olori | Oct 8, 2024
PARAMUS, N.J., October 8, 2024 –– PsychoGenics Inc. (PsychoGenics) today announced it has been awarded a contract by the National Institutes of Health (NIH) to test and identify novel investigational therapeutics for the treatment of pain. The lack of safe and...
by Desiree Cobb-Olori | Aug 28, 2024
PARAMUS, NEW JERSEY, August 28, 2024 – PsychoGenics, a leader in AI-enabled phenotypic drug discovery, has been awarded a Fast Track Small Business Innovation Research (SBIR) grant by NIMH, worth up to $3 million over four years. This grant will support...
by Desiree Cobb-Olori | Jan 24, 2024
We’re excited to introduce more clients to our AI-enabled platforms through an exclusive promotion, available throughout the year. Offer Details: For Contracts of $150,000+: Receive a complimentary SmartCube® study (valued at up to $45,000). For Contracts...
by Desiree Cobb-Olori | Dec 22, 2023
PGI is pleased to be recognized by scientist.com as a top marketplace supplier for 2023.
by Desiree Cobb-Olori | Dec 1, 2023
PsychoGenics is planning the development of RO7117997 for the treatment of multiple CNS conditions starting with sleep and seizure disorders. Paramus, NJ—Dec 1, 2023— PGI Drug Discovery LLC (PsychoGenics), a phenotypic drug discovery platform...
